LLY

770.04

+0.64%↑

JNJ

151.32

+1.12%↑

NVO

69.79

-5.51%↓

ABBV

183.89

-0.62%↓

UNH

300.76

-0.36%↓

LLY

770.04

+0.64%↑

JNJ

151.32

+1.12%↑

NVO

69.79

-5.51%↓

ABBV

183.89

-0.62%↓

UNH

300.76

-0.36%↓

LLY

770.04

+0.64%↑

JNJ

151.32

+1.12%↑

NVO

69.79

-5.51%↓

ABBV

183.89

-0.62%↓

UNH

300.76

-0.36%↓

LLY

770.04

+0.64%↑

JNJ

151.32

+1.12%↑

NVO

69.79

-5.51%↓

ABBV

183.89

-0.62%↓

UNH

300.76

-0.36%↓

LLY

770.04

+0.64%↑

JNJ

151.32

+1.12%↑

NVO

69.79

-5.51%↓

ABBV

183.89

-0.62%↓

UNH

300.76

-0.36%↓

Search

Akebia Therapeutics Inc

Slēgts

SektorsVeselības aprūpe

3.62 -1.09

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

3.48

Max

3.66

Galvenie mērījumi

By Trading Economics

Ienākumi

29M

6.1M

Pārdošana

11M

57M

EPS

0.025

Peļņas marža

10.66

Darbinieki

181

EBITDA

20M

14M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+83.42% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 7. aug.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

324M

935M

Iepriekšējā atvēršanas cena

4.71

Iepriekšējā slēgšanas cena

3.62

Ziņu noskaņojums

By Acuity

100%

0%

363 / 381 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bullish Evidence

Akebia Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 23. jūn. 19:24 UTC

Galvenie tirgus virzītāji

Amgen Expands MariTide Development Plans After Weight-Loss Trial -- Update

2025. g. 23. jūn. 19:07 UTC

Galvenie tirgus virzītāji

Amgen Expands MariTide Development Plans After Successful Weight-Loss Trial

2025. g. 23. jūn. 17:29 UTC

Iegādes, apvienošanās, pārņemšana

FTC Resolves Antitrust Probe Into Omnicom-Interpublic Merger

2025. g. 23. jūn. 23:44 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 23. jūn. 23:44 UTC

Tirgus saruna

Nikkei May Rise as Fears About Israel-Iran Conflict Ease -- Market Talk

2025. g. 23. jūn. 23:39 UTC

Tirgus saruna

Gold Falls After Trump Says Israel, Iran Agree to Cease-Fire -- Market Talk

2025. g. 23. jūn. 23:39 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2025. g. 23. jūn. 22:53 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 23. jūn. 21:42 UTC

Peļņas

KB Home Cuts FY25 Outlook as 2Q Profit, Sales Fall -- Update

2025. g. 23. jūn. 20:50 UTC

Tirgus saruna
Peļņas

Basic Materials Roundup: Market Talk

2025. g. 23. jūn. 20:30 UTC

Tirgus saruna

Canada Employment Data May Be Overstating Job Gains -- Market Talk

2025. g. 23. jūn. 20:24 UTC

Iegādes, apvienošanās, pārņemšana

Tesla Stock Surges After Musk's Robo-Taxi Rollout. Where Shares Go From Here. -- Barrons.com

2025. g. 23. jūn. 20:16 UTC

Tirgus saruna

U.S. Stocks Climb After Iran's Retaliation Seen As Measured -- Market Talk

2025. g. 23. jūn. 19:22 UTC

Tirgus saruna

Oil Futures Sink As Iranian Retaliation Seen Weak -- Market Talk

2025. g. 23. jūn. 18:56 UTC

Tirgus saruna

U.S. Natural Gas Futures Settle Lower -- Market Talk

2025. g. 23. jūn. 18:49 UTC

Tirgus saruna

Gold Ticks Higher in Cautious Trade -- Market Talk

2025. g. 23. jūn. 18:14 UTC

Tirgus saruna

Global Energy Roundup: Market Talk

2025. g. 23. jūn. 18:14 UTC

Tirgus saruna

Treasury Yields, Dollar Little Changed on Iran's Retaliation -- Market Talk

2025. g. 23. jūn. 17:59 UTC

Tirgus saruna

Oil Futures Fall As Iran Fires Missiles At U.S. Bases in Qatar -- Market Talk

2025. g. 23. jūn. 17:25 UTC

Tirgus saruna

Services Lift Mexico's Economic Activity in April -- Market Talk

2025. g. 23. jūn. 17:22 UTC

Tirgus saruna

Weaker Oil Long-Term Looks to Keep a Lid on Grains -- Market Talk

2025. g. 23. jūn. 17:20 UTC

Tirgus saruna

Mexican Inflation Seen Easing in Early June --Market Talk -- Market Talk

2025. g. 23. jūn. 16:27 UTC

Tirgus saruna
Peļņas

Commercial Metals Says Tariffs, Interest Rates Won't Drag on Earnings -- Market Talk

2025. g. 23. jūn. 16:23 UTC

Tirgus saruna
Peļņas

Commercial Metals Sees Resilient Demand, Eyes Growth as Economic Uncertainty Eases -- Market Talk

2025. g. 23. jūn. 16:20 UTC

Tirgus saruna

Energy & Utilities Roundup: Market Talk

2025. g. 23. jūn. 16:20 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2025. g. 23. jūn. 16:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 23. jūn. 16:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 23. jūn. 15:50 UTC

Iegādes, apvienošanās, pārņemšana

Credit Agricole Didn't Disclose Financial Details

2025. g. 23. jūn. 15:49 UTC

Iegādes, apvienošanās, pārņemšana

Credit Agricole: Impact on Credit Agricole's CET1 Ratio Expected to Be Limited

Salīdzinājums

Cenas izmaiņa

Akebia Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

83.42% augšup

Prognoze 12 mēnešiem

Vidējais 6.75 USD  83.42%

Augstākais 8 USD

Zemākais 6 USD

Pamatojoties uz 4 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Akebia Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

4 ratings

4

Pirkt

0

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

2.345 / N/AAtbalsts un pretestība

Īstermiņā

Strong Bullish Evidence

Vidējā termiņā

Strong Bullish Evidence

Ilgtermiņā

Bullish Evidence

Noskaņojums

By Acuity

363 / 381 Rangs Veselības aprūpe

Ziņu noskaņojums

Ļoti spēcīga liecība "Lāču" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Akebia Therapeutics Inc

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.